Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Total Current Liabilities (2016 - 2025)

OptimizeRx (OPRX) has disclosed Total Current Liabilities for 16 consecutive years, with $21.3 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 13.99% to $21.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.3 million through Dec 2025, up 13.99% year-over-year, with the annual reading at $21.3 million for FY2025, 13.99% up from the prior year.
  • Total Current Liabilities hit $21.3 million in Q4 2025 for OptimizeRx, up from $18.5 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $21.3 million in Q4 2025 to a low of $5.4 million in Q1 2021.
  • Historically, Total Current Liabilities has averaged $12.0 million across 5 years, with a median of $8.9 million in 2021.
  • Biggest five-year swings in Total Current Liabilities: tumbled 45.22% in 2021 and later surged 171.45% in 2024.
  • Year by year, Total Current Liabilities stood at $9.4 million in 2021, then decreased by 10.38% to $8.4 million in 2022, then soared by 112.99% to $17.9 million in 2023, then grew by 4.32% to $18.7 million in 2024, then increased by 13.99% to $21.3 million in 2025.
  • Business Quant data shows Total Current Liabilities for OPRX at $21.3 million in Q4 2025, $18.5 million in Q3 2025, and $21.1 million in Q2 2025.